Abstract: The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.

Abstract: The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.

Abstract: Disclosed are occidiofungin formulations and uses thereof for the treatment of proliferative disorders, such as cancer. Methods of producing the disclosed occidiofungin formulations are also provided. Further, methods of treating a subject with the formulations are provided. In some embodiments, the formulations include occidiofungin and one or more cyclodextrins. The formulations may optionally further comprise an additional chemotherapeutic agent for treating the proliferative disease, lipid vesicles, and/or aqueous solvents (including pharmaceutically acceptable buffers and/or exceipients).

Abstract: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.

Abstract: The subject invention pertains to a modified lantibiotic containing an intact cysteine at the C-terminus, particularly, a cysteine that is not decarboxylated and that contains a free carboxyl group. Derivatives of the modified lantibiotic comprising a moiety conjugated to the carboxyl group of the terminal cysteine are also provided. A bacterium that produces a modified lantibiotic having an intact cysteine at the C-terminus are also provided, wherein the bacterium is genetically modified to inactivate a gene that encodes a decarboxylase enzyme that decarboxylates the cysteine at the C-terminus of a precursor lantibiotic. Methods of producing a modified lantibiotic having an intact cysteine at the C-terminus by culturing a bacterium that synthesizes the modified lantibiotic and purifying the lantibiotic are also provided. Mutants of lantibiotics, particularly, mutacin 1140 having higher anti-bacterial activity or higher bacterial expression compared to mutacin 1140 are also provided.

Abstract: A method of transferring an edible image to a substrate includes mounting a printing plate having an image to a roller; depositing an edible adhesive on the image; transferring the edible adhesive to a substrate; and depositing an edible coating on the adhesive coated substrate thereby transferring a mirror copy of the image onto the substrate. The method may further include placing the edible image in contact with foodstuff and applying pressure or a vacuum to transfer the edible image to the foodstuff. The edible image can be placed onto a foodstuff and light pressure or vacuum can be applied to transfer the image. The foodstuff can be held under pressure or vacuum until the image has transferred.

Abstract: A non-detonable source of at least one of an explosive or explosive vapor is disclosed, as well as a method of preparing the explosive or explosive vapor that includes the step of mixing the explosive with at least 50% inert material which retains the explosive vapor until heat is applied.

Abstract: A hood assembly is disclosed for use with a machine having a power source and an operator station. The hood assembly may have a hood configured to at least partially cover the power source, and a hinge located at an end of the hood away from the operator station. The hood assembly may also have a fender located at a transverse side of the hood, and a handle formed within one of the fender and the hood at an end near the operator station.

Abstract: The present invention is directed to novel antifungal glycopeptide compounds and salts thereof produced by a strain of Burkholderia contaminans useful for preventing or treating fungal infection or disease in animals and plants and the bacterial strain that produces the compounds.

Abstract: A hood assembly is disclosed for use with a machine having a power source and an operator station. The hood assembly may have a hood configured to at least partially cover the power source, and a hinge located at an end of the hood away from the operator station. The hood assembly may also have a fender located at a transverse side of the hood, and a handle formed within one of the fender and the hood at an end near the operator station.

Abstract: An alarm system that abuts against a barrier to help prevent entry. The alarm system includes a support portion, such as a tripod. The support portion forms a footprint for firmly pressing against the barrier at an angle. The footprint includes uneven lengths for the legs, a small distance between the ends of each leg, a brace that securely joins each leg, and support portion mounts that join to the ends of the legs for entrenching firmly into the ground surface. A mounting portion at the other end of the support portion includes a collar shape that is configured to engage a barrier fastener, such as a door knob. The support portion tilts against the barrier to resist a force from the opposite side of the barrier. An alarm portion with a sensor detects a force from the door and emits an alarm as required.